Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Radiochimica Acta

International Journal for chemical aspects of nuclear science and technology

Editor-in-Chief: Qaim, Syed M.


IMPACT FACTOR 2018: 1.339

CiteScore 2018: 1.20

SCImago Journal Rank (SJR) 2018: 0.333
Source Normalized Impact per Paper (SNIP) 2018: 0.720

Online
ISSN
2193-3405
See all formats and pricing
More options …
Volume 100, Issue 2

Issues

Radiotracers for SPECT imaging: current scenario and future prospects

Sudeshna Adak / R. Bhalla / K. K. Vijaya Raj / S. Mandal / R. Pickett / S. K. Luthra
Published Online: 2012-01-16 | DOI: https://doi.org/10.1524/ract.2011.1891

Abstract

Single photon emission computed tomography (SPECT) has been the cornerstone of nuclear medicine and today it is widely used to detect molecular changes in cardiovascular, neurological and oncological diseases. While SPECT has been available since the 1980s, advances in instrumentation hardware, software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper.

The biggest change in the last decade has been the fusion of CT with SPECT, which has improved attenuation correction and image quality. Advances in collimator design, replacement of sodium iodide crystals in the detectors with cadmium zinc telluride (CZT) detectors as well as advances in software and reconstruction algorithms have all helped to retain SPECT as a much needed and used technology.

Today, a wide spectrum of radiotracers is available for use in cardiovascular, neurology and oncology applications. The development of several radiotracers for neurological disorders is briefly described in this review, including [123I]FP-CIT (DaTSCANTM) available for Parkinson's disease. In cardiology, while technetium-99m labeled tetrofosmin and technetium-99m labeled sestamibi have been well known for myocardial perfusion imaging, we describe a recently completed multicenter clinical study on the use of [123I]mIBG (AdreViewTM) for imaging in chronic heart failure patients. For oncology, while bone scanning has been prevalent, newer radiotracers that target cancer mechanisms are being developed. Technetium-99m labeled RGD peptides have been reported in the literature that can be used for imaging angiogenesis, while technetium-99m labeled duramycin has been used to image apoptosis.

While PET/CT is considered to be the more advanced technology particularly for oncology applications, SPECT continues to be the modality of choice and the workhorse in many hospitals and nuclear medicine centers. The cost of SPECT instruments also makes them more attractive in developing countries where the cost of a scan is still prohibitive for many patients.

Keywords: Nuclear medicine; 99m-Technetium; 123-Iodine; Oncological imaging; Neurological imaging

About the article

* Correspondence address: GE Healthcare Medical Diagnostics, John F Welch Technology Center, Bangalore, 560066, Indien,


Published Online: 2012-01-16

Published in Print: 2012-02-01


Citation Information: Radiochimica Acta International journal for chemical aspects of nuclear science and technology, Volume 100, Issue 2, Pages 95–107, ISSN (Print) 2193-3405 , DOI: https://doi.org/10.1524/ract.2011.1891.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
S. Chaturvedi, A. Kaul, Puja P. Hazari, and Anil K. Mishra
Med. Chem. Commun., 2017, Volume 8, Number 5, Page 855
[3]
Matthew P. Taggart, Mark D. Tarn, Mohammad M. N. Esfahani, Daniel M. Schofield, Nathaniel J. Brown, Stephen J. Archibald, Tom Deakin, Nicole Pamme, and Lee F. Thompson
Lab Chip, 2016, Volume 16, Number 9, Page 1605
[4]
S. Ted Treves, Alison Goodkind, and F. D. Grant
Clinical and Translational Imaging, 2016, Volume 4, Number 2, Page 119
[5]
Takeshi Fuchigami, Ayaka Ogawa, Yuki Yamashita, Mamoru Haratake, Hiroyuki Watanabe, Masahiro Ono, Masao Kawasaki, Sakura Yoshida, and Morio Nakayama
Bioorganic & Medicinal Chemistry Letters, 2015, Volume 25, Number 16, Page 3363
[6]
Swarndeep K. Sethi, Raunak Varshney, Sandhya Rangaswamy, Nidhi Chadha, Puja P. Hazari, Ankur Kaul, Krishna Chuttani, Marilyn D. Milton, and Anil K. Mishra
RSC Adv., 2014, Volume 4, Number 91, Page 50153
[7]
Moumita Maiti, Kaustab Ghosh, Tania M. Mendonça, Thierry Stora, and Susanta Lahiri
Journal of Radioanalytical and Nuclear Chemistry, 2014, Volume 302, Number 2, Page 1003
[8]
Amanda M. Johnsen, Chuck Z. Soderquist, Bruce K. McNamara, and Darrell R. Fisher
Applied Radiation and Isotopes, 2013, Volume 82, Page 158
[9]
Christa Nilsson, Brianda Barrios-Lopez, Annukka Kallinen, Pasi Laurinmäki, Sarah J. Butcher, Mari Raki, Janne Weisell, Kim Bergström, Susan Weng Larsen, Jesper Østergaard, Claus Larsen, Arto Urtti, Anu J. Airaksinen, and Anan Yaghmur
Biomaterials, 2013, Volume 34, Number 33, Page 8491
[10]
Mónica Fernández-Perea, Marie-Anne Descalle, Regina Soufli, Klaus P. Ziock, Jennifer Alameda, Sherry L. Baker, Tom J. McCarville, Veijo Honkimäki, Eric Ziegler, Anders C. Jakobsen, Finn E. Christensen, and Michael J. Pivovaroff
Physical Review Letters, 2013, Volume 111, Number 2

Comments (0)

Please log in or register to comment.
Log in